MONOPAR THERAPEUTICS (MNPR): Price and Financial Metrics


MONOPAR THERAPEUTICS (MNPR): $3.50

0.14 (+4.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNPR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNPR Stock Price Chart Interactive Chart >

Price chart for MNPR

MNPR Price/Volume Stats

Current price $3.50 52-week high $4.88
Prev. close $3.36 52-week low $1.39
Day low $3.15 Volume 123,400
Day high $3.54 Avg. volume 26,128
50-day MA $2.63 Dividend yield N/A
200-day MA $2.24 Market Cap 45.22M

MONOPAR THERAPEUTICS (MNPR) Company Bio


Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.


MNPR Latest News Stream


Event/Time News Detail
Loading, please wait...

MNPR Latest Social Stream


Loading social stream, please wait...

View Full MNPR Social Stream

Latest MNPR News From Around the Web

Below are the latest news stories about MONOPAR THERAPEUTICS that investors may wish to consider to help them evaluate MNPR as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!

William White on InvestorPlace | December 20, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | December 15, 2022

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS). The data are displayed in the poster that NUS and Monopar

Yahoo | December 12, 2022

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

Yahoo | November 18, 2022

Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | November 18, 2022

Read More 'MNPR' Stories Here

MNPR Price Returns

1-mo 46.44%
3-mo 70.73%
6-mo 72.30%
1-year 21.62%
3-year -82.05%
5-year N/A
YTD 47.68%
2022 -26.17%
2021 -47.55%
2020 -63.13%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7089 seconds.